Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells $74,416.02 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the sale, the insider directly owned 223,640 shares of the company’s stock, valued at $5,103,464.80. This represents a 1.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $22.11 on Friday. The stock has a market cap of $895.23 million, a price-to-earnings ratio of 147.40 and a beta of 0.21. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. The business has a 50-day simple moving average of $21.70 and a 200 day simple moving average of $23.50. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The business had revenue of $196.87 million during the quarter, compared to analysts’ expectations of $201.93 million. During the same period in the previous year, the business earned $0.91 EPS. The business’s revenue was up 5.1% on a year-over-year basis. On average, research analysts forecast that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hantz Financial Services Inc. grew its position in Pacira BioSciences by 175.4% during the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after acquiring an additional 721 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Pacira BioSciences by 5,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after acquiring an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Pacira BioSciences in the 4th quarter valued at $48,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Pacira BioSciences in the 4th quarter valued at $51,000. Finally, Global Retirement Partners LLC grew its holdings in shares of Pacira BioSciences by 479.4% during the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after purchasing an additional 1,678 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on PCRX. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Barclays began coverage on shares of Pacira BioSciences in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price objective on the stock. Zacks Research downgraded shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a report on Monday, March 9th. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.75.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.